According to the new market research report “Aptamers Market by Product Type (DNA, RNA, XNA), Technology (SELEX), Application (Therapeutics, Diagnostics, R&D), End Users (Pharmaceutical & Biotechnology Companies, Academic & Government Research Institutes, CROs) – Global Forecast to 2026″, published by MarketsandMarkets™, is valued at an estimated USD 151 million in 2021 and is projected to reach USD 342 million by 2026, at a CAGR of 17.7% during the forecast period.
Drivers: Rising awareness of the advantages of aptamers over antibodies;
While antibodies have certain limitations in targeting small molecules, aptamers perform better in targeting small molecules. They can bind to small molecules and dyes and thus be easily used in conventional diagnostic kits, extending their use to point-of-care diagnostics. This, in turn, will ensure a greater market value and increase in acceptance of aptamers in addressing both therapeutic and diagnostic applications. Also, aptamers can bind to large molecules. Nearly 98% of the molecules tend to be proteins, making it easier to discover biomarkers and diagnostic kits.
Antibodies are developed by raising an immune response in an animal model or recombinant DNA technology. On the other hand, aptamers can be synthesized using chemical methods which are less costly. Therefore, aptamers are more appealing for the development of new therapeutic drugs and diagnostic kits.
The blood-brain barrier has been a great challenge for antibody-based treatment for neurodegenerative disorders such as Alzheimer’s. Although technological developments have bridged the gap for this challenge, the effectiveness of antibodies against these disorders remains intact. Aptamers are short oligonucleotides that can diffuse across this blood-brain barrier and show potential in treating neurodegenerative disorders.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1167
The Growth of aptamers market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages of aptamers as compared to antibodies, rising investment in pharmaceutical R&D, and rising prevalence of chronic and rare diseases to increase the demand for aptamer-based therapeutics and diagnostics.
Growth in the venture capital funding for research on aptamers and growing collaborations with research institutes and pharmaceutical companies are also expected to offer a wide range of growth opportunities to players in the market. On the other hand, low market acceptance as compared to antibodies is likely to restrain the market growth while shortage of skilled & trained professionals may challenge market growth to a certain extent.
Lower production cost and higher stability will drive the DNA-based aptamers segment growth
Based on type, the aptamers market is segmented into DNA aptamers, XNA aptamers, and RNA aptamers. The DNA-based aptamers segment dominated the market in 2020. The large share of this segment is attributed to their lower production cost and higher stability compared to other nucleic acid-based aptamers and the wide availability of DNA aptamers.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=1167
Others segment is expected to witness the highest CAGR during the forecast period
Based on technology, segmented into SELEX and other technologies. The SELEX technology segment dominated the market in 2020. The segment accounts for a large share of the aptamers market as SELEX is one of the most widely used technologies. The other technologies segment is expected to register the highest CAGR during the forecast period due to the increasing focus on developing technologies for aptamer selection.
North America was the largest regional market for aptamer market in 2020
The global aptamers market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the market. The largest share of North America is attributed to the availability of funds to develop innovative technologies, the presence of prominent market players, and growing collaborations among companies.
Some of the prominent players operating in Aptamers Market include Aptamer Group (UK), Raptamer Discovery Group (US), SomaLogic Inc. (US), Aptamer Sciences, Inc. (South Korea) and Aptagen, LLC (US).
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=1167
